Vivos management to present at 11:30 am Eastern Time on March 16, 2021
Colorado, March 1, 2021
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief Executive Officer, Brad Amman, Chief Financial Officer and Ed Loew, Investor Relations Officer, will conduct meetings with investors at the 33rd Annual ROTH Conference, to be held virtually from March 15-17, 2021.
Institutional investors interested in one-on-one meetings with Vivos management should contact their ROTH Capital institutional sales representative.
Vivos Therapeutics, Inc. will be presenting at the conference on Tuesday, March 16, 2021 at 11:30 am Eastern Time. Investors interested in joining the Vivos presentation can register at the link below:
The conference will feature presentations from public and private companies across a variety of industry sectors. During previous events, ROTH has hosted close to 550 participating companies and attracted more than 5,000 attendees, including institutional investors, analysts, family offices and high-net-worth investors.
A replay of the presentation will be available for view following the presentation on Vivos’ website at: https://vivoslife.com/investor-relations/
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim,” “may,” “could,” “expects,” “projects,” “intends,” “plans,” “believes,” “predicts,” “anticipates,” “hopes,” “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including, without limitation, the anticipated benefits of Australian regulatory approval described here on the Company’s sales and ability to obtain regulatory approvals in other countries) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Vivos Investor Relations Contact:
Investor Relations Officer